Indian drug maker Cipla has signed a deal with Salix Pharmaceuticals allowing the US-based company exclusive rights relating to the Rifaximin Complexes patent family.
US biotechnology company Gilead has agreed a licensing deal with seven Indian drug makers that will enable them to sell a generic version of a drug used to treat hepatitis C.
Biopharmaceutical company Epirus has said that India’s drug regulator has approved a biosimilar application to produce a version of a popular arthritis treatment drug.
A newly revealed malware could be looking to attack the pharmaceutical sector in order to steal IP, a report has claimed.
Law firm Kilpatrick Townsend & Stockton LLP has bolstered its Californian team with the appointment of a new pharmaceutical IP specialist.
UK-based law firm Carpmaels & Ransford LLP has announced the appointment of two new partners to its London office.
Bristol-Myers Squibb has accused pharmaceutical company Merck of infringing a patent covering a method used to treat cancer.
The Australian government department responsible for IP has suggested abolishing a committee that looks after plant breeders’ rights as it looks at alternative means for giving advice to breeders.
Companies in Australia will be able to continue to patent human genes after a court rejected an appeal by a breast cancer survivor.
Magistrate judge Christopher Burke has recommended that the US District Court for the District of Delaware affirm a motion to dismiss a patent infringement case related to the patent eligibility of subject matter, as laid out in 35 USC §101.